Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dyadic International, Inc. - Common Stock
(NQ:
DYAI
)
0.7292
-0.0158 (-2.12%)
Streaming Delayed Price
Updated: 1:29 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyadic International, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Dyadic International Earnings Perspective: Return On Capital Employed
↗
March 30, 2023
Via
Benzinga
Dyadic to Present at World Vaccine Congress Washington 2023
March 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Earnings Outlook For Dyadic International
↗
March 28, 2023
Via
Benzinga
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
March 15, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Recap: Dyadic International Q1 Earnings
↗
May 12, 2022
Dyadic International (NASDAQ:DYAI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform
↗
April 13, 2022
Via
Benzinga
Why Phibro Shares Are Trading Higher Today?
↗
February 10, 2022
Phibro Animal Health Corp (NASDAQ: PAHC) and Dyadic International Inc (NASDAQ: DYAI) have entered into an
Via
Benzinga
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
March 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
March 01, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
February 10, 2023
Via
Benzinga
Dyadic to Participate in Two Upcoming Investor Conferences
February 02, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Sale of Equity Interest in Alphazyme
January 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA...
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
December 14, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
↗
December 05, 2022
During Monday's session, 49 companies made new 52-week lows.
Via
Benzinga
Dyadic to Present at Upcoming Industry and Investor Events in November
November 07, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
October 27, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
October 27, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
October 04, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic International: Q2 Earnings Insights
↗
August 10, 2022
Dyadic International (NASDAQ:DYAI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Preview: Dyadic International
↗
August 09, 2022
Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement.
Via
Benzinga
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
July 27, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic International Earnings Perspective: Return On Capital Employed
↗
March 30, 2022
Dyadic International (NASDAQ:DYAI) brought in sales totaling $313.29 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 145.67%, resulting in a loss of $4.21...
Via
Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
↗
March 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
A Preview Of Dyadic International's Earnings
↗
March 28, 2022
Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Dyadic...
Via
Benzinga
This Vaccine Stock Is Now On Janssen Pharmaceuticals, J&J, The White House's Radar
↗
January 04, 2022
Dyadic International shares were up over 6% on January 3rd. Shares are up over 35% in the last month.
Via
Talk Markets
Earnings Scheduled For March 29, 2022
↗
March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
↗
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
63 Biggest Movers From Friday
↗
December 20, 2021
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
